C75

Cat. No.: HY-12364 Purity: 99.91%: FAQs
Data Sheet SDS COA Handling Instructions

C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM. C75 is a potent CPT1A activator.

For research use only. We do not sell to patients.

C75 Chemical Structure

CAS No. : 218137-86-1

Size	Price	Stock	Quantity
Solution
10 mM * 1 mL in DMSO	USD 132	In-stock	Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL ready for reconstitution	USD 132	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 120	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 199	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 842	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 20 publication(s) in Google Scholar

Other Forms of C75:

trans-C75 In-stock

17 Publications Citing Use of MCE C75

Proliferation Assay

: C75 purchased from MCE. Usage Cited in: Cell Death Discov. 2022 Oct 28;8(1):431. [Abstract]; Transwell migration assay. C75 reduces the migration ability of NUPR1-overexpressing SK-Hep1 cells.

: C75 purchased from MCE. Usage Cited in: Cell Death Discov. 2022 Oct 28;8(1):431. [Abstract]; Cell Counting Kit-8 (CCK8) assay. NUPR1 overexpression-induced proliferation of MHCC-97H and SK-Hep1 cells can be reversed by C75 (50 μM; 48 h).

: C75 purchased from MCE. Usage Cited in: Am J Cancer Res. 2020 Feb 1;10(2):595-609. [Abstract]; Of the transcription of spliced X-box-binding protein 1 (sXBP1) and phosphorylated translational initiation factor 2 in eukaryotes (eIF2α) are higher in ANGTPL4-/- macrophages but are restored to normal levels following C75 treatment.

Featured Recommendations

•Related Screening Libraries:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM^[1]^[2]^[3]. C75 is a potent CPT1A activator^[5].

IC₅₀ & Target

IC50: 35 μM (PC3 cell)^[1]

In Vitro

C75 inhibits PC3 cell growht with an IC₅₀ of 35 μM at 24 h. C75 (10-50 μM) also reduces the growth of LNCaP spheroids in a concentration-dependent manner with an IC₅₀ of 50 μM^[1]. (-)-C75 inhibits FAS activity and has a cytotoxic effect on tumor cell lines, without affecting food consumption. (+)-C75 inhibits CPT1 and its administration produces anorexia, suggesting that central inhibition of CPT1 is essential for the anorectic effect of C75. The differential activity of C75 enantiomers may lead to the development of potential new specific drugs for cancer and obesity^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

C75 blocks fasting-induced c-Fos expression in the arcuate nucleus (Arc), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN) 10–24 h after i.p. injection. Intraperitoneal administration of C75 at 30 mg/kg body weight inhibits food intake of mice by ≥95% within 2 h after i.p. injection^[3]. C75-treated DIO mice has a 50% greater weight loss, and a 32.9% increased production of energy because of fatty acid oxidation. C75 treatment of rodent adipocytes and hepatocytes and human breast cancer cells increases fatty acid oxidation and ATP levels by increasing CPT-1 activity, even in the presence of elevated concentrations of malonyl-CoA^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

254.32

Appearance

Solid

Formula

C₁₄H₂₂O₄

CAS No.

218137-86-1

SMILES

O=C(C(C1=C)C(CCCCCCCC)OC1=O)O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 83.3 mg/mL (327.54 mM)

H₂O : < 0.1 mg/mL (ultrasonic) (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9321 mL	19.6603 mL	39.3205 mL
5 mM	0.7864 mL	3.9321 mL	7.8641 mL
10 mM	0.3932 mL	1.9660 mL	3.9321 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution
4.

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% saline
Solubility: ≥ 1.25 mg/mL (4.92 mM); Clear solution
5.

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in saline)
Solubility: ≥ 1.25 mg/mL (4.92 mM); Clear solution
6.

Add each solvent one by one: 5% DMSO 95% corn oil
Solubility: ≥ 1.25 mg/mL (4.92 mM); Clear solution

*All of the co-solvents are available by MCE.

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (278 KB) SDS (251 KB)

COA (245 KB) LCMS (91 KB)

Handling Instructions (2659 KB)

References

[1]. Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy. [Content Brief]

[2]. Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity. Chirality. 2013 May;25(5):281-7. [Content Brief]

[3]. Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5628-33. [Content Brief]

[4]. Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502. [Content Brief]

[5]. Yan Xue, et al. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation. 2021 Mar 1;105(3):550-560. [Content Brief]

Cell Assay ^[1]	Cells are seeded in 96-well plates and incubated for 2 days to allow exponential phase growth. Cells are then ished twice with PBS and treated with C75. After 24 or 48 h incubation, MTT is added to a final concentration of 0.5 mg/ml and cultures are incubated for 2 h. Cells are then solubilized with DMSO before measuring absorbance at 570 nm. Cell growth is also measured, using MTT assay, every 24 h up to 96 h^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice: C75 is administered either by i.p. (i.p.; 30 mg/kg of body weight) or i.c.v. (10 μg in 3 μL of RPMI medium 1640) injection. One, 11.5, and 24 h after i.p. injection, cumulative food intake is measured, mice are killed, brains are sectioned, and slices are subjected to immunohistochemical staining for c-Fos. All i.p. injections are given 1 h before the start of the dark cycle. For i.c.v. injection, mice are anesthetized with metofane and given 3 μl of RPMI medium 1640 (control) or C75 in RPMI medium 1640 into the lateral ventricle with a calibrated 10-μl Hamilton syringe^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy. [Content Brief] [2]. Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity. Chirality. 2013 May;25(5):281-7. [Content Brief] [3]. Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5628-33. [Content Brief] [4]. Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502. [Content Brief] [5]. Yan Xue, et al. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation. 2021 Mar 1;105(3):550-560. [Content Brief]

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Keywords:

C75218137-86-1C 75C-75Fatty Acid Synthase (FASN)Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email address *

Phone number *

Organization name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name			Lot #
Applicant Name *			Email address *
Phone number			Department *
Organization name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

C75

Customer Review

Other Forms of C75:

17 Publications Citing Use of MCE C75

Featured Recommendations

•Related Screening Libraries:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

Request for HNMR Report